Sold as Moctanin. Every FDA application for this active ingredient.
As of Nov 14, 2026, FDA lists 1 application for Monoctanoin (sold as Moctanin), first approved Oct 29, 1985, with 0 new uses approved and 0 published complete response letters.
| Study | Phase | Status | Posted |
|---|---|---|---|
| Safety, Tolerability, and Pharmacokinetics (PK) of Single and Multiple Ascending Oral Doses of iQ-007Drug Resistant Epilepsy, Focal Seizure · iQure Australia Pty Ltd | Phase 1 | Active, not recruiting | Mar 27, 2025 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
